Enhanced Simian Adenovirus Vectors for Vaccine Development

The present invention relates to improved adenoviral vectors derived from chimpanzee adenovirus AdY25, optimized for enhanced immunogenicity and high-throughput production, and their use in vaccine development.

Traditional adenoviral vectors have limitations in terms of immunogenicity and production efficiency. The original patent disclosed adenoviral vectors derived from chimpanzee adenovirus AdY25, but these vectors still have room for improvement. The present invention addresses these limitations by introducing novel methods and systems for optimizing the vector genome, enhancing immunogenicity, and improving production efficiency.

The inventive concept comprises a series of direct improvements and enhancements to the original adenoviral vectors. Firstly, the vector genome is optimized through codon optimization and/or gene deletion to enhance immunogenicity. Secondly, a system for high-throughput production and purification of the adenoviral vectors is disclosed. Thirdly, a vaccine composition comprising the optimized adenoviral vector and an adjuvant to enhance immunogenicity is described. Fourthly, a method for administering the adenoviral vector vaccine via a mucosal route is disclosed. Finally, a kit for generating the optimized adenoviral vector is provided, comprising the chimpanzee adenovirus AdY25 genome, a nucleic acid molecule, and a set of instructions for optimizing the vector genome.

The inventive concept introduces novel methods and systems for optimizing the adenoviral vector genome, enhancing immunogenicity, and improving production efficiency, which are not disclosed in the original patent. The specific combination of codon optimization, gene deletion, high-throughput production, and mucosal administration provides a new and non-obvious solution to the limitations of traditional adenoviral vectors.

Alternative embodiments of the inventive concept include the use of different chimpanzee adenovirus serotypes, varying the exogenous nucleotide sequence of interest, and incorporating additional genetic elements to enhance immunogenicity. Variations of the system for high-throughput production and purification may include different purification methods or scalable manufacturing processes.

The inventive concept has significant commercial potential in the vaccine development industry, particularly for diseases such as malaria, where traditional vaccine approaches have been impractical. The improved adenoviral vectors could be used in a variety of vaccine applications, including prophylactic and therapeutic vaccines, and could be licensed to biotechnology and pharmaceutical companies for further development and commercialization.